Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Charles River lays off around 70 staffers in relocation as strategic shift begins
(2d)
VC Sofinnova ropes in €650M for biotech, medtech despite 'volatile' environment
(2d)
Sensei shrinks workforce by 65%, terminates 3 executive roles
(2d)
Merck & Co pays $9.2B for owner of influenza antiviral that Janssen rejected
(2d)
BMS and J&J's blood thinner flunks phase 3, denting big blockbuster hopes
(2d)
Analysts skeptical Applied Tx can get rare disease drug to market as FDA talks drag on
(2d)
Chutes & Ladders—Ovid eyes next chapter with CEO transition
(3d)
European investor Medicxi secures €500M biotech fund
(3d)
Pfizer finalizes Metsera buy after contentious bidding war with Novo Nordisk
(3d)
Century, Candel and MacroGenics call time on certain clinical trials to conserve cash
(3d)
Third Arc Bio pens back-loaded $840M pact for Adagene’s masking T-cell engager tech
(3d)
Day One pens $285M deal for Mersana and its clinical-stage B7-H4 ADC
(3d)
Zealand hits pause on dual GLP-1/GLP-2 asset as CMO cites 'increasingly crowded' metabolic development scene
(3d)
Sanara MedTech drops tissue health platform as part of corporate revamp
(3d)
Korro lays off 34% of staff as lead drug disappoints and Novo Nordisk pauses pact
(3d)
Novartis' resistance-busting malaria drug GanLum hits phase 3 goal
(3d)
Grail sees Q3 sales jump, eyes Q1 for FDA Galleri PMA submission
(3d)
Promega wins FDA approval as companion diagnostic for Keytruda-Lenvima combo in uterine cancer
(3d)
Genetic medicine outfit nChroma sheds staff in research reorg
(4d)
Prasad, Makary unveil new FDA path for accelerating custom gene editing therapies
(4d)
BioPharma Dive
Sofinnova Partners raises another $750M to back biotech, medtech startups
(2h)
To Wall Street, a new bidding war puts Alkermes in a tough spot
(2d)
Bristol Myers, J&J’s new blood thinner fails first big test
(2d)
Lundbeck sparks bidding war with Alkermes; Pfizer closes Metsera deal
(2d)
Merck stakes $9.2B on Cidara and its long-acting flu drug
(2d)
Medicxi closes fifth fund to back ‘asset-centric’ startups
(2d)
Day One snaps up ADC maker Mersana in backloaded buyout deal
(3d)
Korro to cut staff, shift strategy as RNA editing drug misses mark in early testing
(3d)
Novartis, with study success, to seek approval of new kind of malaria drug
(4d)
FDA unveils new regulatory roadmap for bespoke drug therapies
(4d)
Richard Pazdur, longtime FDA oncology leader, to head agency’s main drug office
(4d)
Metagenomi, Ovid CEOs step aside; Cogent soars on ‘unprecedented’ stomach cancer data
(4d)
Neurocrine chalks up a depression drug failure
(6d)
FDA to remove safety warnings on hormonal menopause therapy
(6d)
Roche’s MS tablet scores in late-stage studies
(6d)
Merck showcases data suggesting PCSK9 pill might rival cholesterol-lowering shots
(6d)
Lilly picks up an eye gene therapy in deal with MeiraGTx
(6d)
Pfizer wins bidding war for Metsera with $10B offer
(1w)
CMS to launch model to lower Medicaid drug spending
(1w)
Patient dies in Intellia trial; FDA awards 6 more ‘national priority’ vouchers
(1w)
Endpoints News
Sofinnova secures $750M for eleventh fund focused on drugmakers nearing the clinic
(1h)
Inside the Metsera bidding war; PD-(L)1xVEGF bispecific race heats up; Pazdur tapped as next CDER head; and more
(1d)
FDA updates Sarepta’s Duchenne gene therapy label, requests postmarketing study
(2d)
Onshoring and data 'fidelity': What FDA wants from generic drug user fee talks
(2d)
CHMP endorses Sanofi diabetes drug, Lilly breast cancer drug
(2d)
Zhejiang Doer Biologics unveils first-in-class tri-agonist for high lipids
(2d)
Bristol Myers, J&J’s next-gen blood thinner fails key trial in another setback for factor XI
(2d)
Pfizer reduces stake in BioNTech; Candel pauses pancreatic cancer program
(2d)
Cartesian to pause work in form of lupus, despite trial success
(2d)
Exclusive: The inside story of Pfizer and Novo's fight for the $10B Metsera deal
(2d)
Lundbeck fires the first shot in a bidding war with Alkermes over sleep biotech Avadel
(2d)
Merck to buy Cidara and its preventive influenza biologic for $9.2B
(2d)
Mikael Dolsten removes himself from board candidacy at Novo; Bavarian Nordic chairman resigns
(2d)
Vicebio and Versanis backer Medicxi closes new €500M biotech fund
(2d)
FDA approves Kura and Kyowa Kirin's drug for form of acute myeloid leukemia
(3d)
Law to end government shutdown also seeks to accelerate prescription-to-OTC switches
(3d)
UK gives drugmakers third extension to opt out of medicine rebate scheme
(3d)
Pfizer closes up to $10B deal with obesity biotech Metsera
(3d)
Hims launches lab testing for preventive care
(3d)
Regulating mental health chatbots
(3d)
BioSpace
BMS Jettisons Coronary Trial for J&J-Partnered Anticoagulant
(2d)
Bayer Layoffs Continued in Q3 but CEO Says Cuts Should Be ‘Incremental’ Moving Forward
(2d)
Another Bidding War Breaks as Lundbeck Bids for Sleep Biotech Avadel
(2d)
Merck Again Brings Out Big Bucks, Buys Cidara in $9.2B Antiviral Push
(2d)
Gilead Looks to Simplify HIV Treatment By Combining Two Leading Drugs In One Pill
(2d)
Pfizer Reportedly Planning to Divest BioNTech Stake
(2d)
How the FDA Is Accelerating Cell and Gene Therapy’s Next Chapter
(2d)
Pfizer Closes Metsera Deal, Officially Ending Bidding War Drama
(3d)
FDA's Bad Rap: Pazdur Steps Up as Agency Continues To Take on Water
(3d)
Korro Suffers Cacophony of Bad News as Lead Candidate Fails, Novo Pauses RNA Deal
(3d)
Zealand Freezes Mid-Stage Obesity Asset to Focus on More Differentiated Drugs
(3d)
AbbVie Ends 11-Year Relationship With Calico, Lays Off 100+
(3d)
Alkermes Pushes Narcolepsy Program to Phase III With ‘Highly Competitive’ Mid-Stage Data
(3d)
FDA Unwraps ‘Plausible Mechanism Pathway’ for Personalized Therapies
(3d)
Recently Launched Third Arc Turns to China for Cancer T Cell Engagers
(3d)
How Biotech Funding is Changing Executive Search and Hiring Processes
(3d)
FDA Action Alert: BMS, Bayer, Arrowhead and More
(3d)
21 Companies Miss Massachusetts Hiring Targets, Affecting Hundreds of Jobs
(3d)
When, Not If: Job Market Should Start Turning Around in Next Year or So, Experts Say
(3d)
Biohaven Seeks $150 Million From Wall Street Following FDA Rejection
(4d)
STAT News
I spent two hours telling a chatbot about mental health problems. Its responses scared me
(1d)
A close friend grapples with James Watson’s complicated legacy
(1d)
Medicare premiums to jump 10% heading into 2026
(2d)
Pfizer closes $10 billion Metsera deal
(2d)
Judge says he’ll approve opioid settlement with OxyContin maker Purdue and Sackler family
(2d)
Celebrating a new, faster path to gene-editing medicines on demand
(2d)
Advocates decry intersex exceptions in trans health bans
(2d)
Up and down the ladder: The latest comings and goings
(2d)
NIH abruptly places outspoken critic of Trump administration on leave
(2d)
We’re reading about a Merck acquisition, Novo facing shareholder backlash, and more
(2d)
More Americans use weight loss drugs like Ozempic than live in Texas
(2d)
Next-generation blood thinner from Bristol Myers Squibb, J&J fails key trial
(2d)
Merck to buy Cidara, maker of a flu prevention drug, for $9.2B
(2d)
ByHeart’s ‘bizarre’ response to infant botulism outbreak worries food safety experts
(2d)
Why might a 79-year-old man need an MRI of his brain?
(2d)
The era of safe bets in psychiatric medicine is over
(2d)
Merck’s heart disease win and the FDA’s new drug regulator
(3d)
Kura Oncology secures approval for leukemia drug, its first
(3d)
GOP ACA proposal complicates negotiations
(3d)
Makary, Prasad outline pathway for bespoke gene therapy
(3d)
BioPharma Trend
Insilico and Eli Lilly Launch $100M Collaboration for AI-Driven Drug Discovery
(6d)
Insilico Presents Eight Oral Cardiometabolic Drug Candidates Designed With AI
(1w)
Companies Making Automated Drug Discovery a Reality
(2w)
Five Companies Leading the Way in 3D Bioprinting
(2w)
Roche and Manifold Bio's $55M-to-$2B Deal to Develop Next-Gen Brain Shuttles for Neurological Diseases
(2w)
Flatiron Health Launches Six AI Blood Cancer Datasets Covering 505,000 Patients
(3w)
Recursion Unveils Whole-Genome Microglia Map With Roche and Genentech
(3w)
New Foundation Model Reportedly Surpasses AlphaFold 3 in Drug-Protein Binding Prediction
(3w)
Flagship Unveils AI Covalent Chemistry Startup; $50M Commitment and Pfizer Program
(3w)
Iambic Reports Early Clinical Activity of AI-Designed HER2 Inhibitor
(4w)
AstraZeneca and AI-Powered Immune Mapping Company Immunai Sign Up To $85M IBD Target Agreement
(1mo)
Takeda Expands AI-Driven Antibody Design Partnership with Nabla Bio in a Billion-Dollar Deal
(1mo)
AI and CRISPR—converging revolutions in biomedicine?
(1mo)
Sanofi Licenses BenchSci’s Neurosymbolic AI for Global Preclinical RD
(1mo)
AI Model Built on Transformer Architecture Maps 1,300 Mouse Brain Regions in Data-Driven Atlas
(1mo)
AstraZeneca Signs $555 Million AI Deal With Algen For CRISPR Therapies
(1mo)
Singapore’s Nanyang Biologics Plans to Go Public on Nasdaq in US $1.5 Billion SPAC Deal
(1mo)
DARPA Funds PolarisQB to Advance Quantum-Aided Drug Design
(1mo)
BigHat Introduces AI Platform for Antibody Design and Optimization
(1mo)
Why AI Needs to Be at the Center of mRNA Design
(1mo)
Drug Channels
The $700 Copay That Changed Everything
(2d)
Medicare Part D 2026: Preferred Networks Vanish as the PDP Market Collapses
(3d)
Drug Channels Outlook 2026: Live Webinar with Adam J. Fein, Ph.D., on PBMs, Part D, DTC Strategies, Drug Policy Trends, and More
(4d)
Hubs, AI, and the New Era of Revenue Protection in Patient Access
(1w)
As Pharma Faces Financial Pressure, Pharmacy Delivers Measurable Impact
(2w)
Cigna’s Rebate-Free Pharmacy Model: Three Realities Behind Its Latest Push to Pop the Gross-to-Net Bubble
(3w)
Drug Channels News Roundup, October 2025: Vertical Integration Woes, AFPs Gone Wild, Part D’s Decline, 340Bloat, and Dr. G’s ACIP Haunting
(3w)
Let’s Be DIRECT: We Have an Access and Affordability Problem to Solve
(3w)
The Future of Buy-and-Bill Market Access: Five Drivers of Wholesalers’ Vertical Integration with Physician Practices
(4w)
Informa Connect’s Trade and Channel Strategies
(4w)
Why Site of Care Is the Hidden Barrier in Neurology’s Bright Pipeline
(1mo)
NOW AVAILABLE: The 2025–26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors
(1mo)
Informa Connect’s Pharma/Biotech GTN Summit
(1mo)
Direct-to-Patient 2.0: Why Today’s DTP Programs Can’t Scale—and What Pharma Must Do Next
(1mo)
The 340B Contract Pharmacy Market in 2025: Big Chains and PBMs Tighten Their Grip (rerun)
(1mo)
2024 Gross-to-Net Realities at 9 Top Drugmakers: A New Era of Market Access (rerun)
(1mo)
The Stelara Biosimilar Price War: How PBM-Affiliated Private Labels Are Reshaping the Market (rerun)
(1mo)
Informa Connect’s PBM Contracting Summit
(1mo)
Reimagining Patient Access: Building Direct-to-Consumer Models for a New Regulatory Era
(1mo)
Drug Channels News Roundup, September 2025: Mark Cuban Wins (Again), Biosimilar Pricing Double Standards, Part D Collapse, Fresh 340B Facts, and The Pitt
(1mo)
European Biotechnology Magazine
Sofinnova Partners surpasses target with €650m fund to back up early-stage biotech
(2h)
Medicxi announces new €500m biotech investment fund
(18h)
Virometix: US$15m for Synthetic Vaccines
(2d)
Antibodies: Cornerstone of ADC precision and efficacy
(3d)
Scripta Therapeutics raises $12m to flip the script on drug discovery
(4d)
AZ’s baxdrostat mets endpoint in resistant hypertension
(5d)
AstraZeneca bolsters obesity portfolio with muscle‑preserving buy
(6d)
From method validation to the life-cycle
(6d)
SciVario®twin: One Controller for All Your Needs
(6d)
Breakthrough study reveals stability key for mRNA
(6d)
Semaglutide and tirzepatide significantly improve heart health
(1w)
CDMO: An SAP S/4HANA transformation in
(1w)
Eli Lilly and Novo Nordisk slash obesity drug prices
(1w)
QIAGEN acquires Parse Biosciences Inc for US$225m
(2w)
Unlock the Power of Structural Biology
(2w)
Boehringer Ingelheim in US$570m deal with CDR-Life
(2w)
Evolving Antibody Innovation: New frontiers in cancer RD
(2w)
AAVantgarde secures $141m Series B funding
(2w)
How T3 scaled faster in Basel’s biotech labs
(2w)
Novo and Pfizer in Metsera takeover battle
(2w)
Drug Hunter
taletrectinib
(2d)
Will a New Binding Approach Reinvigorate Caspase-1 as a Therapeutic Target for Autoimmune Disorders?
(3d)
nerandomilast (BI 1015550)
(4d)
monepantel (NUZ-001)
(5d)
sepiapterin (PTC 923)
(6d)
CHF6333
(1w)
Reimagining Druggability Using Chemoproteomic Platforms
(1w)
Patenting Strategies for Small Molecule Drugs
(1w)
PAD Inhibitors: Multiple Approaches Have Striven to Make it to Clinical Development
(1w)
AG-270
(2w)
zoliflodacin (ETX-0914)
(2w)
Oncogenic Hyperactivation Lethality: Moving from Concept to Clinic
(2w)
PRT3645
(2w)
September 2025 Patent Highlights
(2w)
venetoclax
(3w)
NVP-EGT710
(3w)
September 2025
(3w)
gepotidacin
(3w)
tinlarebant
(3w)
lenacapavir (GS-6207)
(4w)
Labiotech.EU
10 gene therapy companies you should know about
(2d)
Meet Fusix Biotech: 2025 BIO-Europe Startup Spotlight champion revolutionizing oncology
(2d)
iGEM Jamboree: leap into the synthetic biology future
(3d)
Biosimilars: a vital remedy for Europe’s healthcare challenges
(3d)
Swiss biotech going strong in 2024: 19 companies to put on your radar
(4d)
New cancer cell discovery sheds light on childhood blood cancer
(4d)
BIO Europe partnering: Australian biotech companies share their experiences
(6d)
Top biotech deals in October 2025
(1w)
Next‑generation UTI diagnostics: delivering results in just 35 minutes
(1w)
Novo Nordisk’s pipeline plan: How the pharma giant is refocusing amid major restructuring
(2w)
Treating endometriosis: what lies ahead?
(2w)
The biggest biotech funding rounds in October 2025
(2w)
Rethinking protein production: Why Pichia pastoris is gaining ground in biotech
(2w)
AAVantgarde closes $141 million series B round to tackle inherited eye diseases
(2w)
Spooky science: lab-grown breakthroughs or nightmares?
(2w)
How AI Is revolutionizing synthetic biology and biomanufacturing
(2w)
Parkinson’s disease: biotech’s pursuit for more therapies
(3w)
Eight AI deals in 2025: Discover where industry leaders are betting big
(3w)
The 11 most advanced microbiome players aiming for the gut
(3w)
The ESMO 2025 digest: Is oncology in good shape?
(3w)
Bio IT World
Why Are We Focused on Simulation-based Methods for Predicting Binding Affinity?
(2d)
Why Overlooking Female Biology Still Impairs Drug Development
(4d)
United Genetic, Epigenetic Readouts From The Same DNA Molecule
(5d)
Revolutionizing ADC Manufacturing: How Single-Use Technologies Are Reshaping Biopharma Efficiency and Safety
(1w)
DNA Nanotech Brings Precision Drug Monitoring to At-Home Use
(2w)
PacBio Aims for Sub-$300 Genomes with Reusable SMRT Cells
(2w)
NVIDIA Unveils Quantum-AI Integration and Record-Breaking Blackwell Architecture at GTC 2025
(2w)
SandboxAQ Releases New AI Model, Illumina Launches New Business, Thermo Fisher’s New Analyzer
(3w)
Follow the Money: Potential Best-in-Category Weight Loss Drug Tubulis’ ADC Advancement, Trojan Horse Treatment for Cancer
(3w)
AI Model Turns Health Data Into Disease Forecasts
(3w)
Multiomics Approach Predicts Rheumatoid Arthritis Before First Joint Swelling
(4w)
Longitude Prize on ALS Announces Judge Panel
(4w)
uniQure’s Huntington’s Disease Trial Shows Promising Results
(1mo)
New Immunotherapy Approach Hits the Sweet Spot with Solid Tumors
(1mo)
TOR Inhibitors Could One Day Be Multi-Purpose Healthspan Drugs
(1mo)
Boltz Upgrade: Recursion Researchers Release Pipeline Combining AI Binding Model with Absolute Binding Free Energies
(1mo)
Former Musician Casey McPherson Tackles Rare Disease Cures Through Biotech
(1mo)
Pistoia Alliance Tackles Agentic AI in Pharmaceutical Research
(1mo)
Call for Entries: 2026 Bio-IT World Innovative Practices Award
(1mo)
Quest is on for a ‘Super-Tolerable’ Weight-Loss Drug
(1mo)
GEN News
StockWatch: Korro Craters 81% on Data; Patient Death Sours Analysts on Intellia
(2h)
Merck to Acquire Cidara for $9.2B, Bolstering Antiviral Pipeline
(1d)
Cervical Cancer May Be Treatable with Intranasal Nanogel Vaccine
(1d)
AI Model Could Boost Liver Transplant Efficiency by Predicting Donor Death Timing
(2d)
AI Meets Genetic Agency at Dyno GATC 2025
(2d)
Optical Genome Mapping Links Chromosomal Changes to Recurrent Pregnancy Loss
(2d)
A Future Beyond Animal Testing: Why ORIVA Matters and How Computational Models Bridge the Gap
(2d)
Magnetically Guided Microrobots Deliver Drugs with Pinpoint Accuracy
(2d)
Genetic Agency on Display at GATC 2025
(3d)
Accelerating Clinical Decisions Through Faster Access to Imaging Data
(3d)
Multiomics Reveals Immune Drivers of Pig Kidney Rejection in Humans
(3d)
The Next Superintelligence Will Not Just Think. It Will Bleed.
(3d)
Common Epstein–Barr Virus Reprograms B Cells to Drive Lupus
(3d)
Brain Knowledge Platform Provides AI Models, Data for Disease Studies
(3d)
Targeting Ceramides Prevents Acute Kidney Injury in Mice
(4d)
New Genes Found to Regulate Glycosylation of Immunoglobulin
(4d)
Africa Needs a Vaccine Ecosystem with CDMO and Supplier Support
(4d)
Machine-Learning-Assisted mAb Yield Improvement
(4d)
Cracking the Code of Protein Production in CHO Cells
(4d)
Novel Nasal Spray Vaccine for Pertussis Shows Promise
(4d)
Cure Today
Understanding Stage 2 Vaginal Cancer: Symptoms, Diagnosis, and Treatment
(7h)
Understanding Stage 2 Myeloma with Treatment and Next Steps Explained
(11h)
An Overview of Pancreatic Neuroendocrine Tumors (PNETs)
(1d)
Osteosarcoma Guide: Stages, Treatment, Side Effects and Patient Journey
(1d)
TKIs Take Lead After Immunotherapy in Metastatic Kidney Cancer
(2d)
Higher BMI Linked to Better Survival in Localized Kidney Cancer
(2d)
Kidney Cancer Disparities Persist Among American Indian and Alaskan Native Patients
(2d)
Tribute to My Husband: A Partner Who Shows Up
(2d)
Understanding That Not All Lung Cancer Cases Are Linked to Smoking
(2d)
FDA Fast Tracks FOG-001 After Early Tumor Shrinkage in Desmoid Tumors
(2d)
Breaking Down Advancements in Prostate Cancer Care
(2d)
Living With Purpose After a Metastatic Diagnosis
(3d)
Shared Loss Leads to Lifelong Friendship in Rare Cancer Caregiving
(3d)
FDA Approves First Interchangeable Biosimilar to Perjeta in HER2+ Breast Cancer
(3d)
When One Blood Draw Could Tell More: A Look at the Cancerguard Test
(3d)
FDA Grants Drug Designation to Tinostamustine for Malignant Glioma
(3d)
FDA Approves Komzifti for NPM1-Mutant Acute Myeloid Leukemia
(3d)
Experts Highlight Notable Advances in Colorectal Cancer at 2025 ESMO
(3d)
Cancer Experts Share Emerging Treatments Patients Should Know in 2026
(4d)
Breast Cancer Survivor Advocates for Access to Scalp Cooling
(4d)
Contract Pharma
Contracting & Outsourcing 2025: Q&A with John Bender of Woodstock
(2d)
Merck 3Q Results
(2d)
Pfizer 3Q Results
(2d)
Abbvie 3Q Results
(2d)
TandemAI Secures $22M Series A Extension
(2d)
Merck to Acquire Cidara Therapeutics
(2d)
Cytovance Biologics Celebrates 20 Years in Oklahoma City
(3d)
Neurvati Neurosciences Appoints New Chief Commercial Officer
(3d)
Domain Therapeutics Names Jean-Marie Cuillerot as Chief Medical Officer
(3d)
JSR Life Sciences to Transfer Crown Bioscience to Adicon Holdings Ltd.
(3d)
Mark Egerton Appointed Chairman of Panthera Biopartners
(4d)
SCRI, BMS Expand Collaboration to Accelerate Patient Enrollment
(4d)
Leukogene Therapeutics Receives Funding for Cancer Therapies
(4d)
Ananda Scientific, Benta SAS Sign MOU to Advance Treatments for PTSD
(4d)
Strategic Outsourcing for Supply Chain Resilience: Elevating Biomanufacturing through ExellenS™ in a Complex World
(4d)
BostonGene, Kyoto University Enter Research Collaboration
(4d)
Generics Manufacturing: CDMO Selection & Innovation are Keys to Success
(5d)
acCELLerate, ATCC Partner to Accelerate R&D of New Pharmaceuticals
(5d)
AES Cleanroom Expands with New Office in Research Triangle Park
(5d)
Prokarium Names Ibs Mahmood as CEO
(5d)
Pharma Times
Eisai shares long-term data on lecanemab at neurology congress
(3d)
Mursla Bio partners with global pharma to advance precision medicine in liver disease
(3d)
Evotec earns milestone payment as FDA clears IND for CELMoD candidate
(4d)
Adocia unveils new long-acting peptide platform for diabetes and obesity
(4d)
Real-world data shows AUSTEDO improves life for patients with tardive dyskinesia
(5d)
MSD’s oral cholesterol drug shows promise in late-stage trial
(5d)
MiNK Therapeutics unveils promising results for agenT-797 in resistant cancers
(6d)
Procysbi approved for NHS Scotland use in rare kidney disorder
(6d)
Heidelberg Pharma sees promising results in multiple myeloma trial
(1w)
Christie NHS Foundation Trust harnesses AI to revolutionise patient care
(1w)
Advanced therapies boost UK’s life sciences ambitions
(2w)
Santhera reports promising long-term data for AGAMREE in Duchenne muscular dystrophy
(2w)
CNX Therapeutics acquires Sativex from Jazz Pharmaceuticals
(2w)
bimekizumab data shows sustained benefits in hidradenitis suppurativa
(2w)
ProImmune unveils ProVE SL monomers to boost T cell research
(2w)
Alys Pharmaceuticals begins phase 1/1b trial of ALY-301 for chronic urticaria
(2w)
Advanced therapies boost UK life sciences ambitions
(2w)
Sonoma Biotherapeutics reports promising early data from phase 1 rheumatoid arthritis trial
(3w)
Lincolnshire CDCs boost diagnostics with cutting-edge CT and ultrasound systems
(3w)
Opzelura shows strong results in phase 3b trial for moderate atopic dermatitis
(3w)
Medcity News
Why Shared Savings Still Isn’t a Viable Business Model for Hospitals
(2h)
Startup Iambic Raises $100M for Clinical Trials of AI-Discovered Cancer Drugs
(9h)
Late-in-Life Autism Diagnosis: Why Adults Still Face So Many Barriers and How We Can Do Better
(12h)
Food Is Medicine Needs Data To Thrive
(12h)
Merck Makes Big Antiviral Move With $9B Deal to Land Cidara’s Late-Stage Drug for Flu Prevention
(2d)
Bridging the Gap Between Data and Quality Improvement for Hospitals
(2d)
How to Choose the Right Dental Supply Company for Your Practice
(2d)
AI Companies That Invest in Better Data Pipelines are Winning Faster Regulatory Approvals — Here’s Why
(2d)
What Excites Zimmer Biomet’s CIO About MedTech Right Now?
(2d)
Despite Competition, All Big 4 Ambient Company CEOs Believe They Will Succeed
(3d)
Pluto Health, Help.AI Team Up to Advance Surgical Care
(3d)
FDA Approves Kura Oncology Leukemia Drug, Teeing Up Competition With Syndax Pharma
(3d)
Pivot Podcast: How AI Is Reshaping Care Navigation and Patient Outcomes with Shannon Skaggs
(3d)
AI Clinical Decision Support: Revolutionizing the Doctor’s Black Bag
(3d)
Turning CMS’ Guidelines into a SNF Playbook
(3d)
The Path to Fair PBM Competition
(3d)
Cigna Launches Mental Health Collaboration with Headspace
(4d)
Novel Novartis Malaria Drug Shows Promise to Become New Asset Against Resistant Strains
(4d)
The 340B Program’s New Rebate Pilot Won’t Fix Its Problems
(4d)
Turning AI Insights into Meaningful Action: The Future of Healthcare Navigation
(4d)
Chemical & Engineering News
Formula-linked infant botulism outbreak prompts food safety questions
(2d)
Nov. 14 Policy Watch: US government reopens, is absent from COP 30 climate conference
(2d)
Small molecule targets glucose processing to slow tumor growth
(2d)
ACS elects first zone councilors
(2d)
Woolly mammoth RNA extracted and sequenced
(2d)
Topsoe plant promises 30% efficiency boost for green hydrogen
(2d)
Chemical maker Ineos files 10 lawsuits, is hit with 1
(2d)
Crossword: ‘Say aha!’
(2d)
Chemical makers see cause for optimism in financial results
(3d)
Will quantum computing be chemistry’s next AI?
(3d)
A guide to making gukulenin A
(3d)
Solstice, a new chemical company, rises from Honeywell
(3d)
Obituary: John “Jack” Bishop
(3d)
Green chemistry doesn’t need a federal boost. No, really
(3d)
Comment: The future of American Chemical Society meetings
(4d)
How chemistry can save sounds of the past
(4d)
A breakup strategy that’s inspiring clinical candidates for cancer
(4d)
Unmasking the molecules behind our emotions
(4d)
A bacterial coculture produces cellulose in 7 different colors
(4d)
Beautiful leftovers
(4d)
The Pharma Letter
The week in pharma: action, reaction and insight – week to November 14
(15h)
November EMA/CHMP batch of novel medicines backed for approval
(1d)
Switzerland seen as a safe haven for the life sciences
(1d)
March Biosciences
(2d)
Modulight Biotherapeutics
(2d)
Blood thinner failure thins BMS shares
(2d)
Series A extension takes TandemAI fundraising beyond $80 million
(2d)
Hair loss pipeline looking thicker as investors plough $270 million into a cure for balding
(2d)
Terumo BCT names new head of cell and gene therapy business
(2d)
Biokin delays Hong Kong debut as biotech sentiment cools
(2d)
Merck to buy Cidara Therapeutics in $9.2 billion deal
(2d)
Lundbeck makes unsolicited offer for Avadel Pharmaceuticals
(2d)
Day One to buy cut-price Mersana in deal worth $285 million
(2d)
Medicxi announces 500 million-euro Fund V
(2d)
Carlos Martin named Neurvati CCO
(2d)
Third extension to UK VPAG 2026 decision deadline
(2d)
Gate closes $65m series B to push molecular gate drugs into the clinic
(2d)
FDA approves Kura and Kyowa’s Zomzifti
(2d)
Lundbeck targets fast-growing migraine market with Vyepti filing
(2d)
STADA starts new chapter of growth in UK under Craig Shaw’s leadership
(2d)
Targeted Oncology
The Targeted Pulse: FDA Decisions and Clinical Advancements
(14h)
Long-Term Follow-Up Confirms Benefits of Low-Dose Seminoma Treatment
(1d)
FDA Authorizes EXENT System to Aid Myeloma Diagnosis
(2d)
FDA Accepts NDA for 177Lu-edotreotide in GEP-NETs
(2d)
Beyond Biomarkers: Immunophenotyping Emerging as Key to Precision IRAE Management
(2d)
Rethinking Advanced Prostate Cancer: Surprising Finds from a Landmark Study
(2d)
How Resting Immune Cells Could Be the Key to Fighting Prostate CancerHow Resting Immune Cells Could Be the Key to Fighting Prostate Cancer
(2d)
Outcomes of Indirect Treatment Comparison Study of RELATIVITY-047 and CheckMate 067
(2d)
Reviewing Long-Term CLL Treatment With BTK Inhibitor Zanubrutinib
(3d)
FDA Fast Tracks Anti-CD127 Monoclonal Antibody for Acute Lymphoblastic Leukemia
(3d)
CAR T REMS Elimination Eases Burden on Treatment Centers
(3d)
FOG-001 Receives FDA Fast Track Designation in Desmoid Tumors
(3d)
FDA Approves Novel Interchangeable Biosimilar for Pertuzumab in HER2+ Breast Cancer
(3d)
Detalimogene Generates Improved, Compelling Efficacy Signals in NMIBC
(3d)
Resources for Community Oncologists on Specialized Immunotoxicity Management
(3d)
MB-105 Gains FDA RMAT Designation in R/R T-Cell Lymphoma
(3d)
FDA Approves Ziftomenib in NPM1-Mutant Acute Myeloid Leukemia
(3d)
Imneskibart Plus Aldesleukin Yield Antitumor Activity in Melanoma and NSCLC
(3d)
Improving Rural Cancer Care: Insights from Across the Americas
(3d)
Knowledge Gaps and Future Directions
(3d)
MedWatch
Lars Rebien is the new chairman at Novo Nordisk
(2d)
CFO rejects notion that collapsed takeover has had consequences for Bavarian Nordic
(2d)
Lundbeck to acquire Irish biotech company for up to USD 2.25bn
(2d)
Novo Nordisk and Eli Lilly deny claims of collaboration with telehealth company
(2d)
Coloplast board opens door to bonus feast in new CEO hunt
(2d)
Bavarian Nordic CFO: Travel vaccine market share growing in Germany
(2d)
First financial report after acquisition drama: Bavarian Nordic clarifies expectations
(2d)
Lundbeck gets marketing approval for migraine drug Vyepti in Japan
(2d)
100 days with Doustdar: Sacrificing values in the pursuit of change
(2d)
Mikael Dolsten withdraws his candidacy for Novo Nordisk's board
(2d)
Majority of ALK’s China workforce secures new roles with partners
(2d)
Pfizer sells stake in vaccine partner BioNTech
(2d)
Convatec narrows forecast and signals what next year might offer
(3d)
PensionDanmark will vote in favor of new Novo Nordisk board
(3d)
Novo Nordisk partner Korro Bio dives after failed study
(3d)
Zealand Pharma CEO opens up to acquisitions: “We are entering a whole new phase”
(3d)
Zealand Pharma CEO: Metsera bidding war underscores obesity market priority
(3d)
ALK invests heavily in children's allergies after strong quarter
(3d)
Inside the numbers: Production bears the brunt of Novo Nordisk’s historic mass layoffs
(3d)
Sampension and Lægernes Pension will not support new board at Novo Nordisk
(3d)
In The Pipeline
Huge Channels or No Channels: You Pick
(2d)
Biochemical Tungsten - Really
(3d)
Reaction Stirring, Part Two
(4d)
TrkB, BDNF, and Depression
(6d)
Making Pills. But Not Making Them Here.
(1w)
Screening Without Tagging
(1w)
Sarepta: Enough, For God's Sake
(2w)
Taking It Back, The Right Way
(2w)
The Nocebo Effect Hangs Around
(2w)
A Rare Silicon Switch
(2w)
Blasting Through Cells
(3w)
mRNA Vaccines and Immuno-oncology: Good News
(3w)
Tunnel Away
(4w)
When Variant Proteins Aren't Actually the Variant Ones
(4w)
Disordered Enzymes, Oh Dear
(1mo)
Rapamycin's Secrets
(1mo)
The Latest in Automated Analog Generation
(1mo)
Progress in Cancer Vaccines (Really)
(1mo)
The 2025 Nobel Prize in Chemistry: Metal-Organic Frameworks
(1mo)
Where Do We Stand With "Liver-on-a-Chip" Technology?
(1mo)
Pharmaphorum
Sanofi's type 1 diabetes drug poised for EU rollout
(2d)
Lundbeck makes bid for Avadel, trying to displace Alkermes
(2d)
Kura scores FDA okay for rival to Syndax's leukaemia drug
(2d)
Medicxi raises €500m for fifth biotech fund
(2d)
Medicxi raises €500m for latest biotech fund
(2d)
MSD said to be close to $9bn+ deal for flu biotech Cidara
(2d)
Update: MSD's $9.2bn deal for flu biotech Cidara confirmed
(2d)
NICE backs Roche's non-Hodgkin lymphoma drug Columvi
(3d)
AbbVie exits alliance with Alphabet biotech Calico; report
(3d)
Novartis says novel drug could counter malaria resistance
(3d)
FDA unveils swift route to market for personalised drugs
(3d)
Change at the top of Recursion as co-founder leaves CEO role
(3d)
One Drop founder announces broad market CGM on Frontiers stage
(4d)
Alkermes breaks new ground in narcolepsy with orexin drug
(4d)
Bayer beats expectations with tougher times looming
(4d)
AI features in UK plan to reduce animal testing
(4d)
NHS braces for thousands of redundancies
(4d)
FDA appoints veteran Pazdur to replace Tidmarsh
(4d)
Trial sets up filing for enGene bladder cancer gene therapy
(5d)
Daiichi Sankyo launches its STING operation against cancer
(5d)
Drug Discovery Weekly
This week in Drug Discovery (10 – 14 November)
(2d)
New platform hopes to solve strategic misalignment in biopharma
(2d)
Positive data announced for treatment-resistant depression drug
(2d)
Leucid Bio establishes proof-of-concept for CAR-T therapy
(2d)
MHRA approves myopia treatment for children in UK
(2d)
ALS treatment could be worth billions, research suggests
(3d)
Whitepaper: See what’s driving the next wave of degrader discovery
(3d)
See what’s driving the next wave of degrader discovery
(3d)
Radiotherapy drug delivers promising early tumour treatment
(3d)
Covid-19 mRNA vaccine boosts cancer response, study shows
(3d)
Meet the researcher: Catherine Whittington Associate Professor
(3d)
Inflammatory bowel disease drug approved for use in NHS Scotland
(3d)
App Note: Go beyond 2D with 3D live-cell technologies
(3d)
Transform compound screening – Go beyond 2D with 3D live-cell technologies
(3d)
ABPI urges UK government to stop life sciences ‘falling behind’
(4d)
One to watch: How Aulos is advancing immunotherapy cancer treatments
(4d)
How new scientific approaches are accelerating RD
(4d)
Leading the charge in cancer care
(4d)
New method shows ‘sky’s the limit’ for genome editing
(4d)
Apogee Therapeutics announces positive data for I&I antibody
(4d)
HIT Consultant
How Visitor Management Can Make or Break Safety Plans
(2d)
“How to Make Wound Recovery and the Healing Process More Accessible in America”
(2d)
Carrot Partners with ŌURA and Dexcom to Power Metabolic-Fertility Health with Biometric Data
(2d)
Cityblock Health and Mercy Health Partner to Transform Medicaid Care in Ohio
(2d)
CHIME-KLAS: The Digital Health Most Wired National Trends Report 2025
(3d)
Life or Death Logistics: Why 1 in 5 Donated Organs Are Not Transplanted Due to Communication Failure
(3d)
Fundamental XR and Elsevier Launch Mixed Reality Innovation Program for Enterprise AI
(3d)
AISAP Launches FDA-Cleared Platform in Ghana to Solve Cardiologist Shortage
(3d)
How AI Frees Nurses and Clinicians to Focus on Care and Quality
(3d)
AI Risk Alert: Hospitals Underinvest in Governance Despite Looming 2026 Scrutiny
(3d)
Integrating Narrative Medicine into Elder Support Programs
(3d)
Joy Secures $14M to Redefine the Parenting Experience
(3d)
InterSystems Launches: Generative AI AI Assistant for Faster Patient Record Access
(3d)
Digital Health Meets Life Insurance: How Technology Is Redefining Financial Protection and Preventive Care
(3d)
AI Company Matic Extends Automation to Medical Coding and Billing
(4d)
AI Digital Stethoscope Detects Heart Failure with Near-Echo Precision in Ghana
(4d)
Reinventing Value-Based Care Program Administration with AI
(4d)
Sentara Health Deploys Andor Health’s Agentic AI Across 12 Hospitals
(4d)
GE HealthCare and DeepHealth Expand AI Collaboration to Optimize Ultrasound and Breast Cancer Care
(4d)
House Rx Raises $55M to Scale In-Clinic Specialty Pharmacy Model
(4d)
Insights: Pink Sheet
Sarepta’s Elevidys Limited To Ambulatory DMD Patients; Study In Non-Ambulatory Patients Planned
(2d)
Adverse Events: Professional Education, Electronic Records Integration Would Improve Report Quality
(2d)
CNPV II: Secondary Indications Feature In Second Batch Of US FDA Voucher Winners
(2d)
Wiskott-Aldrich Syndrome Gene Therapy Among 10 New Drugs To Win EMA OK
(2d)
EMA Backs Sanofi’s Teizeild For Type 1 Diabetes, Company Holds Fire On Extended Indication In EU
(2d)
UK MHRA Closes RegulatoryConnect Portal Less Than Two Years Post-Launch
(2d)
Is US FDA Biosimilars Office Next In Line For Promotion?
(3d)
Beyond The Hype: AI Use Cases In Drug Development
(3d)
What US FDA’s Pazdur’s Long Oncology Track Record Portends For CDER
(3d)
Brazil Bets On AI To Cut Backlog Of Regulatory Applications
(3d)
New Zealand To Approve Drugs In Just 30 Days Under ‘Rule of Two’ Policy
(3d)
Cancer Drug Trials Must Be Ready To Pivot As Standards Of Care Shift
(4d)
US FDA’s ‘Plausible Mechanism’ Pathway: A Platform-Based Approach Not Just For Rare Diseases
(4d)
Second-Most Favored Nation? CMS Clarifies Medicaid Price Benchmark In GENEROUS Model
(4d)
UK Needs Specialist Scientific Knowledge To Stay Competitive Post-Brexit, AstraZeneca Says
(4d)
‘Why We Would Do It Again’ – Gilead & Roche On Pioneering Global Initiative For Manufacturing Change
(4d)
Novel Alzheimer’s Drug Blarcamesine Scheduled For High-Stakes EMA Oral Explanation
(4d)
The British Pharmacopoeia: Setting standards that are trusted worldwide
(4d)
Hope For Stability, Credibility As US FDA Vet Pazdur Takes Over CDER
(5d)
FY 2025 Generic Drugs By The Numbers
(5d)
BioXconomy
Supporting the growth of clinical trials in Africa
(2d)
Africa’s clinical trial expansion hindered by logistics challenges despite growing population
(2d)
Clinical trial design and operations in genome editing therapeutics
(2d)
BIO-Europe
(2d)
HOTH Therapeutics Presents Early Stage Oncology, Dermatology and Neurology Pipeline
(2d)
Medicxi closes $581m Fund V to accelerate asset-centric biotech investments
(2d)
Immuneering: Atebimetinib MEK Inhibitor for Pancreatic Cancer
(3d)
Industry leaders advocate for balanced IRT sponsor-vendor relationships
(3d)
Women's health investment surges, but systemic barriers remain
(3d)
Tiny peptide CAQK triggers damage repair following traumatic brain injury
(4d)
Jantar GmbH presents dicholine succinate, a new non-prescription drug for the treatment of chronic rhinosinusitis
(4d)
CIS pharmaceutical markets face regulatory hurdles amid geopolitical tensions, industry expert warns
(4d)
RIANA Therapeutics' first in class inhibitors targeting transcription factor for cancer treatment
(4d)
WHO encourages greater inclusion of children in clinical trials
(4d)
Eli Lilly licenses vision-restoring gene therapy for $475m
(4d)
Clinical trial experts share strategies for building flexible IRT systems
(5d)
Organon reports Q3 2025 results following investigation into improper Nexplanon sales practices in US
(5d)
Aurevia lands €3 million contract to run clinical trial of Urteste's pancreatic cancer detection device
(5d)
Eyes on Asia: ABL Bio, Eli Lilly, Celltrion
(5d)
CRISPR's mixed week: Breakthrough heart health treatment and a patient death
(5d)
BioCentury
EMA’s CHMP recommends five new products
(2d)
Catalyst-driven week in venture and public equity: Finance Report
(2d)
FDA’s label changes to Sarepta’s Elevidys address physician concerns
(2d)
‘Sharp focus’ on well-positioned assets to drive Medicxi’s €500M Fund V
(2d)
Pharma’s commercial revolution: How integrated DTC models elevate and empower patients
(2d)
Cidara’s Cinderella year ends with $9.2B Merck takeout bid
(2d)
America welcomed Elias Zerhouni — today the door would be closed
(2d)
MFN scheme is less onerous than expected
(2d)
SITC features bispecific solutions for solid tumors
(3d)
Beijing’s Jacobio unveils two CEO structure, and more C-suite moves
(3d)
Pfizer’s Metsera deal secures fast-working amylin analog
(3d)
Paths to autism treatment: Validating targets for syndromic ASD
(3d)
New heads of neuro, immunology at Lilly, and more biopharma moves
(4d)
Is this Korea’s biotech moment? A BioCentury podcast
(4d)
Brain shuttle field accelerates with three more pharma deals
(4d)
Makary’s plausible mechanism pathway praised as positive step, criticized for vagueness
(4d)
Science Spotlight: How an AAV from Capsida crosses the BBB
(4d)
Science Spotlight: How an AAV from Receptive crosses the BBB
(4d)
In his own words: Pazdur’s letter to CDER staff
(4d)
AstraZeneca impresses with resistant hypertension data at AHA 2025
(5d)